Your browser doesn't support javascript.
Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival.
Loucera, Carlos; Perez-Florido, Javier; Casimiro-Soriguer, Carlos S; Ortuño, Francisco M; Carmona, Rosario; Bostelmann, Gerrit; Martínez-González, L Javier; Muñoyerro-Muñiz, Dolores; Villegas, Román; Rodriguez-Baño, Jesus; Romero-Gomez, Manuel; Lorusso, Nicola; Garcia-León, Javier; Navarro-Marí, Jose M; Camacho-Martinez, Pedro; Merino-Diaz, Laura; Salazar, Adolfo de; Viñuela, Laura; Lepe, Jose A; Garcia, Federico; Dopazo, Joaquin.
  • Loucera C; Bioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.
  • Perez-Florido J; Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of Seville, 41013 Sevilla, Spain.
  • Casimiro-Soriguer CS; Bioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.
  • Ortuño FM; Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of Seville, 41013 Sevilla, Spain.
  • Carmona R; Bioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.
  • Bostelmann G; Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of Seville, 41013 Sevilla, Spain.
  • Martínez-González LJ; Bioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.
  • Muñoyerro-Muñiz D; Department of Computer Architecture and Computer Technology, University of Granada, 18011 Granada, Spain.
  • Villegas R; Bioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.
  • Rodriguez-Baño J; Bioinformatics Area, Andalusian Public Foundation Progress and Health-FPS, 41013 Sevilla, Spain.
  • Romero-Gomez M; GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain.
  • Lorusso N; Subdirección Técnica Asesora de Gestión de la Información, Servicio Andaluz de Salud, 41001 Sevilla, Spain.
  • Garcia-León J; Subdirección Técnica Asesora de Gestión de la Información, Servicio Andaluz de Salud, 41001 Sevilla, Spain.
  • Navarro-Marí JM; Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of Seville, 41013 Sevilla, Spain.
  • Camacho-Martinez P; Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain.
  • Merino-Diaz L; Departamento de Medicina, Universidad de Sevilla, C. San Fernando, 4, 41004 Sevilla, Spain.
  • Salazar A; Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), ISCIII, 28029 Madrid, Spain.
  • Viñuela L; Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of Seville, 41013 Sevilla, Spain.
  • The Andalusian Covid-Sequencing Initiative; Departamento de Medicina, Universidad de Sevilla, C. San Fernando, 4, 41004 Sevilla, Spain.
  • Lepe JA; Servicio de Aparato Digestivo, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
  • Garcia F; Dirección General de Salud Pública, Consejería de Salud y Familias, Junta de Andalucía, 41020 Sevilla, Spain.
  • Dopazo J; Departamento de Metafísica y Corrientes Actuales de la Filosofía, Ética y Filosofía Política, Universidad de Sevilla, 41004 Sevilla, Spain.
Viruses ; 14(9)2022 08 27.
Article in English | MEDLINE | ID: covidwho-2006220
ABSTRACT

OBJECTIVES:

More than two years into the COVID-19 pandemic, SARS-CoV-2 still remains a global public health problem. Successive waves of infection have produced new SARS-CoV-2 variants with new mutations for which the impact on COVID-19 severity and patient survival is uncertain.

METHODS:

A total of 764 SARS-CoV-2 genomes, sequenced from COVID-19 patients, hospitalized from 19th February 2020 to 30 April 2021, along with their clinical data, were used for survival analysis.

RESULTS:

A significant association of B.1.1.7, the alpha lineage, with patient mortality (log hazard ratio (LHR) = 0.51, C.I. = [0.14,0.88]) was found upon adjustment by all the covariates known to affect COVID-19 prognosis. Moreover, survival analysis of mutations in the SARS-CoV-2 genome revealed 27 of them were significantly associated with higher mortality of patients. Most of these mutations were located in the genes coding for the S, ORF8, and N proteins.

CONCLUSIONS:

This study illustrates how a combination of genomic and clinical data can provide solid evidence for the impact of viral lineage on patient survival.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: V14091893

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: V14091893